乙基2-甲基-1-哌嗪羧酸酯 | 120737-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 乙基2-甲基-1-哌嗪羧酸酯
• 英文名称: ethyl 2-methyl-1-piperazinecarboxylate
• 英文别名: 2-methyl-1-ethoxycarbonylpiperazine；1-ethoxycarbonyl-2-methylpiperazine；ethyl 2-methylpiperazine-1-carboxylate
• CAS: 120737-73-7
• 化学式: C₈H₁₆N₂O₂
• 分子量: 172.227
• InChiKey: CWPSTZCYESJGPF-UHFFFAOYSA-N

物化性质

• 沸点：
  246.5±15.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  乙基2-甲基-1-哌嗪羧酸酯 在 氧化亚氮 、 sodium methylate 作用下， 以 甲醇 、 乙醚 为溶剂， 生成 sodium 1-[4-ethoxycarbonyl-3-methylpiperazin-1-yl]diazen-1-ium-1,2-diolate
  参考文献：
  名称：

  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs

  摘要：

  Nitric oxide (NO) prodrugs such as O-2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) are a growing class of promising NO-based therapeutics. Nitric oxide release from the anti-cancer lead compound, JS-K, is proposed to occur through a nucleophilic aromatic substitution by glutathione (GSH) catalyzed by glutathione S-transferase (GST) to form a diazeniumdiolate anion that spontaneously releases NO. In this study, a number of structural analogues of JS-K were synthesized and their chemical and biological properties were compared with those of JS-K. The homopiperazine analogue of JS-K showed anti-cancer activity that is comparable with that of JS-K but with a diminished reactivity towards both GSH and GSH/GST; both the aforementioned compounds displayed no cytotoxic activity towards normal renal epithelial cell line at concentrations where they significantly diminished the proliferation of a panel of renal cancer cell lines. These properties may prove advantageous in the further development of this class of nitric oxide prodrugs as cancer therapeutic agents. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.09.063
• 作为产物：
  描述：

  2-甲基-1,4-哌嗪二甲酸二乙酯 在 氢氧化钾 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以57%的产率得到乙基2-甲基-1-哌嗪羧酸酯
  参考文献：
  名称：

  Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs

  摘要：

  Nitric oxide (NO) prodrugs such as O-2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate (JS-K) are a growing class of promising NO-based therapeutics. Nitric oxide release from the anti-cancer lead compound, JS-K, is proposed to occur through a nucleophilic aromatic substitution by glutathione (GSH) catalyzed by glutathione S-transferase (GST) to form a diazeniumdiolate anion that spontaneously releases NO. In this study, a number of structural analogues of JS-K were synthesized and their chemical and biological properties were compared with those of JS-K. The homopiperazine analogue of JS-K showed anti-cancer activity that is comparable with that of JS-K but with a diminished reactivity towards both GSH and GSH/GST; both the aforementioned compounds displayed no cytotoxic activity towards normal renal epithelial cell line at concentrations where they significantly diminished the proliferation of a panel of renal cancer cell lines. These properties may prove advantageous in the further development of this class of nitric oxide prodrugs as cancer therapeutic agents. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2008.09.063

文献信息

• [EN] PHOSPHONIC ACID DERIVATES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHOSPHONIQUE ET LEUR UTILISATION EN TANT QU'ANTAGONISTES DU RÉCEPTEUR P2Y12
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2009069100A1

  公开（公告）日：2009-06-04

  The invention relates to 2-phenyl-pyrimidine derivatives containing a phosphonic acid motif and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals. (I).

  这项发明涉及含有膦酸基团的2-苯基嘧啶衍生物，以及它们作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况中的使用，包括人类和其他哺乳动物中的血栓形成。（I）。
• N-aryl-piperazinealkanamides useful for improving sleep
  申请人：Janssen Pharmaceutica N.V.

  公开号：US04880808A1

  公开（公告）日：1989-11-14

  A method of improving sleep in warm-blooded animals suffering from sleep disorders, which method comprises the administration of particular N-aryl-piperazinealkanamide derivatives and compositions containing the same. Novel N-aryl-piperazinealkanamide derivatives.

  一种改善患有睡眠障碍的温血动物睡眠的方法，该方法包括给予特定的N-芳基哌嗪烷酰胺衍生物和含有相同物质的组合物。新颖的N-芳基哌嗪烷酰胺衍生物。
• Process for the preparation of quinoline antibacterial compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0350950A1

  公开（公告）日：1990-01-17

  A process for preparing substituted 7-(piperazin-1-yl)-4-oxo-1,4-dihydro-3-quinoline carboxylic acid derivative antibacterial agents by reacting a carbamate protected piperazine derivative with a 7-halo-4-oxo-1,4-dihydro-quinoline carboxylic acid derivative.

  通过将羰酸酯保护的哌嗪衍生物与7-卤代-4-氧代-1,4-二氢喹啉羧酸衍生物反应，制备取代的7-(哌嗪-1-基)-4-氧代-1,4-二氢-3-喹啉羧酸衍生物抗菌剂的方法。
• COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE
  申请人：SHY Therapeutics LLC

  公开号：US20170174699A1

  公开（公告）日：2017-06-22

  Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.

  本文提供了抑制MAPK磷酸化的化合物，因此可用于治疗癌症和炎症性疾病的组合物和方法。
• Pyrimidine Derivatives and Their Use as P2Y12 Receptor Antagonists
  申请人：Caroff Eva

  公开号：US20080194576A1

  公开（公告）日：2008-08-14

  The invention relates to 4-aminocarbonyl-pyrimidine derivatives and their use as P2Y 12 receptor antagonists in the treatment and/or prevention and/or treatment of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  该发明涉及4-氨基甲酰基嘧啶衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏-、肝脏-和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的疾病或状况的用途，包括在人类和其他哺乳动物中的血栓形成。